We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Exelixis (EXEL - Free Report) closed at $23.04 in the latest trading session, marking a -0.39% move from the prior day. This change lagged the S&P 500's daily loss of 0.21%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq lost 0.18%.
Heading into today, shares of the drug developer had gained 9% over the past month, outpacing the Medical sector's gain of 1.11% and the S&P 500's gain of 1.81% in that time.
Wall Street will be looking for positivity from EXEL as it approaches its next earnings report date. The company is expected to report EPS of $0.24, down 34.36% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $216.08 million, up 1.76% from the year-ago period.
EXEL's full-year Zacks Consensus Estimates are calling for earnings of $1.02 per share and revenue of $930.60 million. These results would represent year-over-year changes of -28.67% and +9.17%, respectively.
It is also important to note the recent changes to analyst estimates for EXEL. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 17.17% lower. EXEL currently has a Zacks Rank of #3 (Hold).
Digging into valuation, EXEL currently has a Forward P/E ratio of 22.68. For comparison, its industry has an average Forward P/E of 21.69, which means EXEL is trading at a premium to the group.
Also, we should mention that EXEL has a PEG ratio of 0.77. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. EXEL's industry had an average PEG ratio of 1.57 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 66, which puts it in the top 26% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow EXEL in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know
Exelixis (EXEL - Free Report) closed at $23.04 in the latest trading session, marking a -0.39% move from the prior day. This change lagged the S&P 500's daily loss of 0.21%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq lost 0.18%.
Heading into today, shares of the drug developer had gained 9% over the past month, outpacing the Medical sector's gain of 1.11% and the S&P 500's gain of 1.81% in that time.
Wall Street will be looking for positivity from EXEL as it approaches its next earnings report date. The company is expected to report EPS of $0.24, down 34.36% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $216.08 million, up 1.76% from the year-ago period.
EXEL's full-year Zacks Consensus Estimates are calling for earnings of $1.02 per share and revenue of $930.60 million. These results would represent year-over-year changes of -28.67% and +9.17%, respectively.
It is also important to note the recent changes to analyst estimates for EXEL. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 17.17% lower. EXEL currently has a Zacks Rank of #3 (Hold).
Digging into valuation, EXEL currently has a Forward P/E ratio of 22.68. For comparison, its industry has an average Forward P/E of 21.69, which means EXEL is trading at a premium to the group.
Also, we should mention that EXEL has a PEG ratio of 0.77. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. EXEL's industry had an average PEG ratio of 1.57 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 66, which puts it in the top 26% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow EXEL in the coming trading sessions, be sure to utilize Zacks.com.